Priority

There’s good news on the horizon for people at risk for a type 1 diabetes (T1D) diagnosis, especially parents of young children. Sanofi recently announced that its drug to delay …

Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Tzield (teplizumab-mzwv) targeting young children with stage 2 …

MedWatchUS FDA grants priority review for Sanofi’s type 1 diabetes drugFrance is seeking fast-track approval of diabetes drug Tzield in children aged over one..2 hours ago

Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the …

Jacob T. Wittman, PhD1; Dayna S. Alexander, DrPH1; Melissa Bing, MPH1; Robert Montierth, PharmD, MBA1; Hui Xie, PhD1; Stephen R. Benoit, MD, MPH1; Kai McKeever Bullard, MPH, PhD1 (View author …